Medicine and Dentistry
Temozolomide
100%
Vimentin
100%
Cell Surface
100%
Glioma Stem Cell
100%
Monoclonal Antibody
100%
Glioblastoma
40%
Drug Resistance
30%
Chemotherapy
20%
Combination Therapy
10%
Intracranial Tumor
10%
Programmed Cell Death
10%
Tumor Cell
10%
Blood Brain Barrier
10%
Antiinfective Agent
10%
Sensitization
10%
Target Cell
10%
Stem Cell Line
10%
Specific Tumor
10%
Keyphrases
Monoclonal Antibody
100%
Glioma Stem Cells
100%
Temozolomide
100%
Cell Surface Vimentin
100%
Glioblastoma multiforme
40%
Chemoresistance
20%
Mouse Model
10%
Chemotherapy
10%
Apoptosis
10%
Improved Outcomes
10%
Blood-brain Barrier
10%
Therapeutic Efficacy
10%
Tumor-specific
10%
Brain Tumor
10%
Patient-derived
10%
Promising Strategies
10%
Prolonged Survival
10%
Enhanced Sensitivity
10%
Drug Resistance
10%
Stem Cell Lines
10%
Tumor Cell Survival
10%
Cell Sensitivity
10%
Antitumor Effect
10%
Sensitivity to Chemotherapy
10%
Vimentin Expression
10%
Resistance Sensitivity
10%
Pharmacology, Toxicology and Pharmaceutical Science
Temozolomide
100%
Vimentin
100%
Monoclonal Antibody
100%
Glioblastoma
66%
Drug Resistance
50%
Chemotherapy
33%
Neoplasm
33%
Mouse Model
16%
Antiinfective Agent
16%
Intracranial Tumor
16%
Combination Therapy
16%
Blood-Brain Barrier
16%
Neuroscience
Monoclonal Antibody
100%
Stem Cell
100%
Vimentin
100%
Temozolomide
100%
Glioblastoma Multiforme
40%
Drug Resistance
30%
Cell Line
10%
Blood Brain Barrier
10%
Intracranial Tumor
10%
Immunology and Microbiology
Cell Surface
100%
Monoclonal Antibody
100%
Glioma Stem Cell
100%
Drug Resistance
30%
Mouse Model
10%
Tumor Cell
10%
Sensitization
10%
Target Cell
10%
Blood Brain Barrier
10%
Stem Cell Line
10%